Drugs / risperidone-SABER
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01592110 | Jul 2012 → Apr 2013 | schizophrenia | Zogenix, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | risperidone-SABER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01592110 ↗ |
| Route | Subcutaneous | “administered as a subcutaneous (SC) injection” NCT01592110 ↗ |